(-)-α-[(2-nitrophenyl)amino]-2,6-dichlorobenzeneacetamide | 147362-55-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (-)-α-[(2-nitrophenyl)amino]-2,6-dichlorobenzeneacetamide
• 英文别名: 2-(2,6-Dichlorophenyl)-2-(2-nitroanilino)acetamide
• CAS: 147362-55-8
• 化学式: C₁₄H₁₁Cl₂N₃O₃
• 分子量: 340.166
• InChiKey: BSFPWNBIKBSHRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (-)-α-[(2-nitrophenyl)amino]-2,6-dichlorobenzeneacetamide 在 聚合甲醛 、 碳酸氢钠 作用下， 以 水 为溶剂， 以76.2 parts (68.6%)的产率得到(+/-)-2,6-dichloro-N-(hydroxymethyl)-α-[(2-nitrophenyl)amino]benzeneacetamide
  参考文献：
  名称：

  HIV-inhibiting benzeneacetamide derivatives

  摘要：

  一种用作药物的化合物，其化学式为##STR1## 以及其药学上可接受的酸盐形式或立体化异构体形式，其中R.sup.1和R.sup.2各自独立地为氢、C.sub.1-6烷基或C.sub.3-6环烷基；或者R.sup.1和R.sup.2与带有所述R.sup.1和R.sup.2的氮原子一起形成吡咯啉基、哌啶基、吗啉基、哌嗪基或4-C.sub.1-4烷基哌嗪基；X为O或S；R.sup.3为氢或C.sub.1-6烷基；R.sup.4、R.sup.5和R.sup.6各自独立地为氢、卤素、C.sub.1-6烷基、C.sub.1-6烷氧基、硝基、三氟甲基、氰基、氨甲基、羧基、C.sub.1-4烷氧羰基、C.sub.1-4烷基羰基、氨基羰基或羟基；R.sup.7为氢或卤素；R.sup.8、R.sup.9和R.sup.10各自独立地为氢、卤素、C.sub.1-6烷基、C.sub.1-6烷氧基、硝基、羟基、三氟甲氧基、2,2,2-三氟乙氧基、(三氟甲基)羰基、氨基羰基、(环丙基)羰基或基团C.sub.1-6烷基-(C.dbd.Y)--其中.dbd.Y代表.dbd.O、.dbd.N--OH、.dbd.N--OCH.sub.3、.dbd.N--NH.sub.2或.dbd.N--N(CH.sub.3).sub.2；但条件是（1）当R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6、R.sup.7、R.sup.9和R.sup.10代表氢，R.sup.8代表4-乙氧基，X代表氧时，R.sup.1不是正丙基，以及（2）当R.sup.1、R.sup.2、R.sup.3、R.sup.6、R.sup.7、R.sup.8、R.sup.9和R.sup.10代表氢，R.sup.4和R.sup.5代表3,4-二甲氧基时，X不是硫，新颖的化合物，含有上述化合物的药物组合物以及制备上述组合物的方法。

  公开号：

  US05556886A1
• 作为产物：
  描述：

  (+/-)-α-amino-2,6-dichlorobenzeneacetamide 、 1-氟-2-硝基苯 在 1-氟-2-硝基苯 作用下， 生成 (-)-α-[(2-nitrophenyl)amino]-2,6-dichlorobenzeneacetamide
  参考文献：
  名称：

  HIV-inhibiting benzeneacetamide derivatives

  摘要：

  一种用作药物的化合物，具有以下式子：##STR1## 其中R.sup.1和R.sup.2各自独立地是氢、C.sub.1-6烷基或C.sub.3-6环烷基；或者R.sup.1和R.sup.2与携带R.sup.1和R.sup.2的氮原子一起形成吡咯烷基、哌啶烷基、吗啉基、哌嗪基或4-C.sub.1-4烷基哌嗪基；X为O或S；R.sup.3为氢或C.sub.1-6烷基；R.sup.4、R.sup.5和R.sup.6各自独立地为氢、卤素、C.sub.1-6烷基、C.sub.1-6烷氧基、硝基、三氟甲基、氰基、氨甲基、羧基、C.sub.1-4烷氧羰基、C.sub.1-4烷基羰基、氨基羰基或羟基；R.sup.7为氢或卤素；R.sup.8、R.sup.9和R.sup.10各自独立地为氢、卤素、C.sub.1-6烷基、C.sub.1-6烷氧基、硝基、羟基、三氟甲氧基、2,2,2-三氟乙氧基、(三氟甲基)羰基、氨基羰基、(环丙基)羰基或基团C.sub.1-6烷基-(C.dbd.Y)--其中.dbd.Y代表.dbd.O、.dbd.N--OH、.dbd.N--OCH.sub.3、.dbd.N--NH.sub.2或.dbd.N--N(CH.sub.3).sub.2；条件是（1）当R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6、R.sup.7、R.sup.9和R.sup.10代表氢，R.sup.8代表4-乙氧基，X代表氧时，R.sup.1不是正丙基；（2）当R.sup.1、R.sup.2、R.sup.3、R.sup.6、R.sup.7、R.sup.8、R.sup.9和R.sup.10代表氢，R.sup.4和R.sup.5代表3,4-二甲氧基时，X不是硫。新化合物，含有上述式（I）化合物的制药组合物，以及制备上述组合物的方法。

  公开号：

  US05556886A1

文献信息

• [EN] HIV INHIBITING 1,2,4-TRIAZInONE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,2,4-TRIAZINONE INHIBITEURS DU VIH
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006015985A1

  公开（公告）日：2006-02-16

  The present invention relates to HIV replication inhibitors of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein ring A and ring B represent phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; n and m are 1 to 4; R1 represents hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxy C1-6alkylcarbonyl substituted with C1-6alkyloxycarbonyl; their use as a medicine, their use for the manufacture of a medicament for the treatment or the prevention of HIV infection; their processes for preparation and pharmaceutical compositions comprising them.

  本发明涉及公式(I)的HIV复制抑制剂，其中N-氧化物，药学上可接受的加盐物，季铵盐或其立体化学异构体形式，其中环A和环B代表苯基，吡啶基，吡啶并嗪基，嘧啶基或吡嗪基；n和m为1至4；R1代表氢；芳基；甲酰基；C1-6烷基羰基；C1-6烷氧羰基；可选择取代的C1-6烷基；C1-6烷氧基C1-6烷基羰基，其用作药物，用于制造用于治疗或预防HIV感染的药物的药物，其制备方法和包含它们的制药组合物。
• Prodrugs of hiv replication inhibiting pyrimidines
  申请人：——

  公开号：US20030186990A1

  公开（公告）日：2003-10-02

  The present invention concerns compounds of formula (A 1 )(A 2 )N—R 1 (I),the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof, wherein R 1 is substituted C 1-6 alkyl; —S(═O)—R 8 ; —S(═O) 2 —R 8 ; C 7-12 alkylcarbonyl; optionally substituted C 1-6 alkyloxycarbonylC 1-6 alkylcarbonyl; with R 8 being C 1-6 alkyl, aryl 1 or Het 1 ; (A 1 )(A 2 )N— is the covalently bonded form of the corresponding intermediate of formula (A 1 )(A 2 )N—H, which is a HIV replication inhibiting pyrimidine of formula 1

  该发明涉及化合物的公式(A1)(A2)N—R1(I)，其N-氧化物形式、药用可接受的附加盐、季铵盐和立体化学异构体形式，其中R1为取代的C1-6烷基；—S(═O)—R8；—S(═O)2—R8；C7-12烷基羰基；可选择地取代的C1-6烷氧羰基C1-6烷基羰基；其中R8为C1-6烷基、芳基或Het1；(A1)(A2)N—为公式(A1)(A2)N—H对应中间体的共价结合形式，该中间体为公式1的HIV复制抑制嘧啶。
• HIV REPLICATION INHIBITING PYRIMIDINES
  申请人：——

  公开号：US20030114472A1

  公开（公告）日：2003-06-19

  This invention concerns the use of compounds of formula 1 the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a 1 =-a 2 -a 3 =a 4 - forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R 1 is hydrogen, aryl, formyl, C 1-6 alkylcarbonyl, C 1-6 alkyl, C 1-6 alkyloxy-carbonyl, substituted C 1-6 alkyl, or substituted C 1-6 alkyloxyC 1-6 alkylcarbonyl; each R 2 independently is hydroxy, halo, optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, C 3-7 cycloalkyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C 1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalo-methylthio, —S(═O) p R 6 , —NH—S(═O) p R 6 , —C(═O)R 6 , —NHC(═O)H, —C(═O)NHNH 2 , —NHC(═O)R 6 , —C(═NH)R 6 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl or C 3-7 cycloalkyl; or L is —X—R 3 wherein R 3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR 1 —, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O) 2 —; Q is hydrogen, C 1-6 alkyl, halo, polyhalo-C 1-6 alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C 3-7 cycloalkyl, optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C 1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O) p R 6 , —NH—S(═O) p R 6 , —C(═O)R 6 , —NHC(═O)H, —C(═O)NHNH 2 , —NHC(═O)R 6 , —C(═NH)R 6 or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

  这项发明涉及使用式1化合物，其N-氧化物，药用可接受的加成盐，季铵盐和其立体化学异构体，其中-a1=-a2-a3=a4-形成苯基，吡啶基，嘧啶基，吡啉基或吡嗪基与附加的乙烯基；n为0至4；如可能为5；R1为氢，芳基，甲酰基，C1-6烷基羰基，C1-6烷基，C1-6烷氧羰基，取代的C1-6烷基，或取代的C1-6烷氧基烷基羰基；每个R2独立地为羟基，卤素，可选地取代的C1-6烷基，C2-6烯基或C2-6炔基，C3-7环烷基，C1-6烷氧基，C1-6烷氧羰基，羧基，氰基，硝基，氨基，单或双(C1-6烷基)氨基，多卤甲基，多卤甲氧基，多卤甲硫基，—S(═O)pR6，—NH—S(═O)pR6，—C(═O)R6，—NHC(═O)H，—C(═O)NHNH2，—NHC(═O)R6，—C(═NH)R6或5-成员杂环环；p为1或2；L为可选地取代的C1-10烷基，C2-10烯基，C2-10炔基或C3-7环烷基；或L为—X—R3，其中R3为可选地取代的苯基，吡啶基，嘧啶基，吡嗪基或吡啉基；X为—NR1—，—NH—NH—，—N═N—，—O—，—C(═O)—，—CHOH—，—S—，—S(═O)—或—S(═O)2—；Q为氢，C1-6烷基，卤素，多卤C1-6烷基或可选地取代的氨基；Y代表羟基，卤素，C3-7环烷基，可选地取代的C1-6烷基，C2-6烯基或C2-6炔基，C1-6烷氧基，C1-6烷氧羰基，羧基，氰基，硝基，氨基，单或双(C1-6烷基)氨基，多卤甲基，多卤甲氧基，多卤甲硫基，—S(═O)pR6，—NH—S(═O)pR6，—C(═O)R6，—NHC(═O)H，—C(═O)NHNH2，—NHC(═O)R6，—C(═NH)R6或芳基；芳基为可选地取代的苯基；Het为可选地取代的杂环基团；用于制造治疗感染艾滋病毒（Human Immunodeficiency Virus）的患者的药物。
• 1,5,6,-Substituted-2-Oxo-3-Cyano-1,6a-Diaza-Tetrahydro-Fluoranthenes as Anti-Infective Agents
  申请人：Kesteleyn Bart Rudolf Romanie

  公开号：US20080167296A1

  公开（公告）日：2008-07-10

  HIV inhibitory compounds of formula: salts and stereoisomers thereof, wherein R 1 and R 2 are hydrogen or optionally substituted C 1-10 alkyl; R 3 is n is 1, 2 or 3; R 3a is nitro, cyano, amino, halo, hydroxy, C 1-4 alkyloxy, hydroxycarbonyl, aminocarbonyl, CI 4 alkyloxycarbonyl, mono- or di(C 1-4 alkyl)aminocarbonyl, C 1-4 alkylcarbonyl, methanimidamidyl, mono- or di(C 1-4 alkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het; or R 3 is a monocyclic or bicyclic aromatic heterocyclic ring system, wherein one, two, three or four ring members are nitrogen, oxygen and sulfur, and wherein the remaining ring members are carbon atoms; and wherein each of said heterocyclic ring systems may optionally be substituted; X is —NR 7 —, —0— or —S—; pharmaceutical compositions containing these compounds, methods for preparing these compounds and compositions.

  HIV抑制化合物的结构式：盐及其立体异构体，其中R1和R2是氢或可选择取代的C1-10烷基；R3是n为1、2或3；R3a是硝基、氰基、氨基、卤素、羟基、C1-4烷氧基、羟基羰基、氨基羰基、C1-4烷氧羰基、单取代或双取代的(C1-4烷基)氨基羰基、C1-4烷基羰基、甲酰胺基、单取代或双取代的(C1-4烷基)甲酰胺基、N-羟基甲酰胺基或Het；或R3是单环或双环芳香杂环环系统，其中一个、两个、三个或四个环成员是氮、氧和硫，其余环成员为碳原子；且每个所述杂环环系统可选择地被取代；X为-NR7-、-O-或-S-；含有这些化合物的药物组合物，制备这些化合物和组合物的方法。
• [EN] HIV INHIBITING 5-SUBSTITUTED PYRIMIDINES<br/>[FR] PYRIMIDINES 5-SUBSTITUEES INHIBITRICES DE HIV
  申请人：TIBOTEC PHARM LTD

  公开号：WO2006035069A1

  公开（公告）日：2006-04-06

  HIV replication inhibitors of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein A is -CH2-CH2- , -CH=CH- , -C≡C- ; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, R2 hydroxy, halo, C1-6alkyl, carboxyl, cyano, -C(=O)R6, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl; X1 is -NR1-, -O-, -S-, -S(=O)p-; R3 is H, C1-6alkyl, halo ; R4 is H, C1-6alkyl, halo ; R5 is nitro, amino, mono- and diC1-4alkylamino, aryl, halo, -CHO, -CO-R6, -COOR7, -NH-C(=O)H, -NH-C(=O)R6, -CH=N-O-R8; R6 is C1-4alkyl, amino, mono- or di(C1-4alkyl)amino or polyhaloC1-4alkyl; R7 is hydrogen, C1-6alkyl, arylC1-6alkyl; R8 is hydrogen, C1-6alkyl, aryl; p is 1 or 2; aryl is optionally substituted phenyl; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.

  公式（I）的HIV复制抑制剂，其中A为-CH2-CH2-，-CH=CH-，-C≡C-；R1为氢，芳基，甲酰基，C1-6烷基羰基，C1-6烷基，C1-6烷氧羰基，R2为羟基，卤素，C1-6烷基，羧基，氰基，-C（=O）R6，硝基，氨基，单或双（C1-6烷基）氨基，多卤甲基；X1为-NR1-，-O-，-S-，-S（=O）p-；R3为H，C1-6烷基，卤素；R4为H，C1-6烷基，卤素；R5为硝基，氨基，单和双C1-4烷基氨基，芳基，卤素，-CHO，-CO-R6，-COOR7，-NH-C（=O）H，-NH-C（=O）R6，-CH=N-O-R8；R6为C1-4烷基，氨基，单或双（C1-4烷基）氨基或多卤代C1-4烷基；R7为氢，C1-6烷基，芳基C1-6烷基；R8为氢，C1-6烷基，芳基；p为1或2；芳基为可选取代苯基；含有这些化合物作为活性成分的药物组合物以及制备这些化合物和组合物的过程。